LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 227

Search options

  1. Article: Sunglasses for Sunlight: Considerations on New Treatment Opportunities for Refractory Colorectal Cancer.

    Zaniboni, Alberto

    Cancers

    2024  Volume 16, Issue 7

    Abstract: In 2023, two seminal studies were disseminated that significantly augmented the pharmacological armamentarium for the treatment of refractory metastatic colorectal carcinoma (MCRC) [ ... ]. ...

    Abstract In 2023, two seminal studies were disseminated that significantly augmented the pharmacological armamentarium for the treatment of refractory metastatic colorectal carcinoma (MCRC) [...].
    Language English
    Publishing date 2024-03-29
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers16071348
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Il profilo di tossicità del TAS-102. Considerazioni pratiche in tema di neutropenia.

    Zaniboni, Alberto

    Recenti progressi in medicina

    2019  Volume 110, Issue 7, Page(s) 325–329

    Abstract: TAS-102 represents an important therapeutic resource for patients with metastatic refractory colorectal cancer. Albeit generally well tolerated, clinically relevant neutropenia may interfere with the regular delivery of full-dose cycles with a possible ... ...

    Title translation The toxicity profile of TAS-102. Practical considerations about neutropenia.
    Abstract TAS-102 represents an important therapeutic resource for patients with metastatic refractory colorectal cancer. Albeit generally well tolerated, clinically relevant neutropenia may interfere with the regular delivery of full-dose cycles with a possible detrimental effect on the dose-intensity. Judicious and personalized use of colony-stimulating growth factors as well as alterative schedules of drug delivery could mitigate neutropenia, so contributing to an even better therapeutic index of the drug.
    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/pathology ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Combinations ; Humans ; Neutropenia/chemically induced ; Neutropenia/prevention & control ; Pyrrolidines/administration & dosage ; Pyrrolidines/adverse effects ; Trifluridine/administration & dosage ; Trifluridine/adverse effects ; Uracil/administration & dosage ; Uracil/adverse effects ; Uracil/analogs & derivatives
    Chemical Substances Drug Combinations ; Pyrrolidines ; trifluridine and tipiracil ; Uracil (56HH86ZVCT) ; Trifluridine (RMW9V5RW38)
    Language Italian
    Publishing date 2019-08-04
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 138266-4
    ISSN 2038-1840 ; 0034-1193
    ISSN (online) 2038-1840
    ISSN 0034-1193
    DOI 10.1701/3197.31743
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 193: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Low-Dose Immunotherapy: Is It Just an Illusion?

    Meriggi, Fausto / Zaniboni, Alberto / Zaltieri, Anna

    Biomedicines

    2023  Volume 11, Issue 4

    Abstract: The development and use of immunotherapy in the last decade have led to a drastic improvement in results in the onco-haematological field. This has implied, on the one hand, the need for clinicians to manage a new type of adverse event and, on the other ... ...

    Abstract The development and use of immunotherapy in the last decade have led to a drastic improvement in results in the onco-haematological field. This has implied, on the one hand, the need for clinicians to manage a new type of adverse event and, on the other hand, a significant increase in costs. However, emerging scientific evidence suggests that, as with other drugs in the recent past, the registry dosage can be drastically reduced for immunotherapies without penalizing their effectiveness. This would also lead to an important reduction in costs, expanding the audience of cancer patients who could access immunotherapy-based treatments. In this "Commentary", we analyze the available evidence of pharmacokinetics and pharmacodynamics and the most recent literature in favor of low-dose immunotherapy.
    Language English
    Publishing date 2023-03-27
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2720867-9
    ISSN 2227-9059
    ISSN 2227-9059
    DOI 10.3390/biomedicines11041032
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Optimizing the first-line treatment for metastatic colorectal cancer.

    Cherri, Sara / Oneda, Ester / Zanotti, Laura / Zaniboni, Alberto

    Frontiers in oncology

    2023  Volume 13, Page(s) 1246716

    Abstract: Colorectal cancer represents an important oncological challenge both for its incidence, which makes it an important health problem, and for its biological complexity, which has made clinical results very difficult in terms of outcome for this category of ...

    Abstract Colorectal cancer represents an important oncological challenge both for its incidence, which makes it an important health problem, and for its biological complexity, which has made clinical results very difficult in terms of outcome for this category of patients. To date these diseases should not be treated as a single entity but it is necessary to distinguish colorectal cancers based on characteristics that nowadays are essential to have greater therapeutic benefits. These include the sideness of the disease, the state of microsatellites, the presence of prognostic and predictive mutations of response to treatments currently available in clinical practice, which are associated with new therapeutic targets. The greatest challenge in the future will be to circumvent the resistance mechanisms that make this disease very difficult to treat with good long-term results by studying effective combination treatments with a good toxicity profile. Once such combinations or targeted treatments are consolidated, it will be desirable to shift the best therapies to the first line treatment to make them immediately accessible to the patient. It will also be essential to refine the selection of patients who can benefit from these treatments.
    Language English
    Publishing date 2023-10-16
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2023.1246716
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Adjuvant treatment of colon cancer with microsatellite instability - the state of the art.

    Oneda, Ester / Zaniboni, Alberto

    Critical reviews in oncology/hematology

    2021  Volume 169, Page(s) 103537

    Abstract: Adjuvant chemotherapy with fluoropyrimidine (FP) plus oxaliplatin in stage III resected colorecatal cancer (RCRC) resulted in a 30% relative reduction of disease recurrence risk and mortality. The presence of altered mismatch repair genes identify tumors ...

    Abstract Adjuvant chemotherapy with fluoropyrimidine (FP) plus oxaliplatin in stage III resected colorecatal cancer (RCRC) resulted in a 30% relative reduction of disease recurrence risk and mortality. The presence of altered mismatch repair genes identify tumors with microsatellite instability (MSI) that have a better prognosis than stable tumors, but data about adjuvant chemotherapy benefit in this subgroup are compelling. We investigate the role of adjuvant therapy in resected MSI RCRC. The standard treatment is the association of FP plus oxaliplatin, while it can avoided in low risk stage II, thanks to its good prognosis. We propose a practice strategy to approach MSI RCRC in line with the current knowledge. In consideration of the dramatic results in chemorefractory MSI metastatic CRC, there are assumptions that immunotherapy can become a potential alternative to classical systemic therapies also in the adjuvant setting. We await the results of ongoing studies to draw further conclusions."
    MeSH term(s) Chemotherapy, Adjuvant ; Colonic Neoplasms/drug therapy ; Colonic Neoplasms/genetics ; Colorectal Neoplasms/drug therapy ; DNA Mismatch Repair/genetics ; Fluorouracil/therapeutic use ; Humans ; Microsatellite Instability ; Neoplasm Recurrence, Local/drug therapy ; Prognosis
    Chemical Substances Fluorouracil (U3P01618RT)
    Language English
    Publishing date 2021-11-18
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 605680-5
    ISSN 1879-0461 ; 0737-9587 ; 1040-8428
    ISSN (online) 1879-0461
    ISSN 0737-9587 ; 1040-8428
    DOI 10.1016/j.critrevonc.2021.103537
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1931: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Aflibercept: focus sulla tollerabilità.

    Zaniboni, Alberto

    Recenti progressi in medicina

    2016  Volume 107, Issue 12, Page(s) 647–651

    Abstract: Aflibercept, a potent antiangiogenic agent that exhibits a broad spectrum of antitumor activity, is currently administered in combination with FOLFIRI for the second-line treatment of metastatic colorectal cancer. Here, practical measures to minimize the ...

    Title translation Aflibercept: focus on tolerability.
    Abstract Aflibercept, a potent antiangiogenic agent that exhibits a broad spectrum of antitumor activity, is currently administered in combination with FOLFIRI for the second-line treatment of metastatic colorectal cancer. Here, practical measures to minimize the risk of toxicity in real-world patients are suggested.
    Language Italian
    Publishing date 2016-12
    Publishing country Italy
    Document type Journal Article ; English Abstract
    ZDB-ID 138266-4
    ISSN 2038-1840 ; 0034-1193
    ISSN (online) 2038-1840
    ISSN 0034-1193
    DOI 10.1701/2502.26234
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 193: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors.

    Cherri, Sara / Melocchi, Laura / Gandolfi, Laura / Rossi, Giulio / Zaniboni, Alberto

    Life (Basel, Switzerland)

    2023  Volume 13, Issue 2

    Abstract: In recent years, precision medicine has taken an increasing place in various branches of medical oncology, including colorectal cancer. Among the potentially relevant mutations for this cancer is the KRAS mutation, initially defined as "untargetable"; ... ...

    Abstract In recent years, precision medicine has taken an increasing place in various branches of medical oncology, including colorectal cancer. Among the potentially relevant mutations for this cancer is the KRAS mutation, initially defined as "untargetable"; today, we see the birth of new molecules that target one of the variants of the KRAS mutation, KRAS G12C, having a significant impact on the therapeutic options for other malignancies, such as metastatic lung cancer. This fundamental step forward has stimulated scientific research on other potential targets of KRAS, both indirect and direct, and combination treatments aiming to overcome the mechanisms of resistance to these drugs that decrease in efficacy in colorectal cancer. What was once a negative predictive marker of response to anti-EGFR drugs today has become a potential target for targeted treatments. In turn, the prognostic role of the mutation has become extremely interesting, making it a potentially useful element in therapeutic decision-making, not only regarding oncological treatments but also in a more complex and complete manner within a global vision of the patient, involving other figures on the multidisciplinary team, such as surgeons, radiotherapists, and interventional radiologists.
    Language English
    Publishing date 2023-01-31
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2662250-6
    ISSN 2075-1729
    ISSN 2075-1729
    DOI 10.3390/life13020395
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: New active drugs for the treatment of advanced colorectal cancer.

    Zaniboni, Alberto

    World journal of gastrointestinal surgery

    2015  Volume 7, Issue 12, Page(s) 356–359

    Abstract: Newer active drugs have been recently added to the pharmacological armamentarium for the treatment of metastatic colorectal cancer. Aflibercept, a recombinant fusion protein composed of the extracellular domains of human vascular endothelial growth ... ...

    Abstract Newer active drugs have been recently added to the pharmacological armamentarium for the treatment of metastatic colorectal cancer. Aflibercept, a recombinant fusion protein composed of the extracellular domains of human vascular endothelial growth factor receptors (VEGFR) 1 and 2 and the Fc portion of human immunoglobulin G1 (IgG1), is an attractive second-line option in combination with folfiri for patients who have failed folfox +/- bevacizumab. Ramucirumab, a human IgG1 monoclonal antibody that targets VEGFR-2, provided similar results in the same setting. Tas-102, an oral fluoropyrimidine, and regorafenib, a multi-tyrosine kinase inhibitor, are both able to control the disease in a considerable proportion of patients when all other available treatments have failed. These new therapeutic options along with the emerging concept that previous therapies may also be reitroduced or rechallenged after regorafenib and Tas-102 failure are bringing new hope for thousands of patients and their families.
    Language English
    Publishing date 2015-12-28
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2573700-4
    ISSN 1948-9366
    ISSN 1948-9366
    DOI 10.4240/wjgs.v7.i12.356
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Behind and in front of our masks. A new era in communication with our patients.

    Andreis, Federica / Meriggi, Fausto / Zaniboni, Alberto

    Journal of psychosocial oncology

    2022  Volume 41, Issue 3, Page(s) 372–375

    MeSH term(s) Humans ; Masks ; COVID-19 ; Communication
    Language English
    Publishing date 2022-08-30
    Publishing country United States
    Document type Journal Article
    ZDB-ID 605892-9
    ISSN 1540-7586 ; 0734-7332
    ISSN (online) 1540-7586
    ISSN 0734-7332
    DOI 10.1080/07347332.2022.2113952
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2006: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: L’olfatto e il gusto nei pazienti CoViD-19: il senso dimenticatoTempi di recupero della funzionalità olfattoria e gustativa nei pazienti CoViD-19.

    Gamba, Paolo / Zaniboni, Alberto

    Recenti progressi in medicina

    2020  Volume 111, Issue 10, Page(s) 614–618

    Abstract: Aim: The aim of the retrospective study is to determine whether CoViD-19 positive patients with olfactory and gustatory dysfunction have the ability to recover chemoreceptorial loss, unlike other viral and inflammatory diseases in which the damage is ... ...

    Title translation Smell and taste in CoViD-19 patients: the forgotten sense.
    Abstract Aim: The aim of the retrospective study is to determine whether CoViD-19 positive patients with olfactory and gustatory dysfunction have the ability to recover chemoreceptorial loss, unlike other viral and inflammatory diseases in which the damage is partial and in some cases is permanent.
    Materials and methods: The study examined 75 patients admitted, from March to April 2020, at the Poliambulanza Foundation with CoViD-19. In 53 out of 75 patients, chest X-rays were positive for infiltration and/or pleural effusion. Two weeks after discharge, two rhinopharyngeal swabs were performed with negative results for CoViD-19. Enlisted patients responded to a questionnaire, upon informed consent, called the Questionnaire for Olfactory Dysfunction (QOD) which evaluates the severity of the disorder and social impact. In the second phase of the study we carefully researched the recovery times of olfactory dysfunction and dysgeusia.
    Results and conclusions: The analysis of the scores of the Olfactory Dysfunction Questionnaire CoViD-19 (QOD) recorded the total recovery in all patients of olfactory and gustatory function with an average time of 17.4 days. This study reveals that Coronavirus does not cause a permanent olfactory and gustatory loss. The olfactory and gustatory impairment has been recognized as a distinctive sign of CoViD-19, but should not be considered as a favorable prognostic index.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; COVID-19 ; Coronavirus Infections/complications ; Coronavirus Infections/diagnosis ; Dysgeusia/epidemiology ; Dysgeusia/virology ; Female ; Humans ; Male ; Middle Aged ; Olfaction Disorders/epidemiology ; Olfaction Disorders/virology ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/diagnosis ; Recovery of Function ; Retrospective Studies ; Severity of Illness Index ; Surveys and Questionnaires ; Time Factors
    Keywords covid19
    Language Italian
    Publishing date 2020-10-19
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 138266-4
    ISSN 2038-1840 ; 0034-1193
    ISSN (online) 2038-1840
    ISSN 0034-1193
    DOI 10.1701/3453.34422
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 193: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top